450 related articles for article (PubMed ID: 27802204)
21. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
22. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells.
Maggisano V; Celano M; Lombardo GE; Lepore SM; Sponziello M; Rosignolo F; Verrienti A; Baldan F; Puxeddu E; Durante C; Filetti S; Damante G; Russo D; Bulotta S
Mol Cell Endocrinol; 2017 Jun; 448():34-40. PubMed ID: 28288903
[TBL] [Abstract][Full Text] [Related]
23. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
[TBL] [Abstract][Full Text] [Related]
24. HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1.
Pan Z; Fang Q; Li L; Zhang Y; Xu T; Liu Y; Zheng X; Tan Z; Huang P; Ge M
Cancer Lett; 2021 Mar; 501():31-42. PubMed ID: 33359451
[TBL] [Abstract][Full Text] [Related]
25. S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
Stewart RL; Carpenter BL; West DS; Knifley T; Liu L; Wang C; Weiss HL; Gal TS; Durbin EB; Arnold SM; O'Connor KL; Chen M
Oncotarget; 2016 Jun; 7(23):34630-42. PubMed ID: 27127879
[TBL] [Abstract][Full Text] [Related]
26. Small interfering RNA-directed knockdown of S100A4 decreases proliferation and invasiveness of osteosarcoma cells.
Ma X; Yang Y; Wang Y; An G; Lv G
Cancer Lett; 2010 Dec; 299(2):171-81. PubMed ID: 20855150
[TBL] [Abstract][Full Text] [Related]
27. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
28. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of S100A4 Predicts Migration, Invasion, and Poor Prognosis of Hypopharyngeal Squamous Cell Carcinoma.
Xu J; Gross N; Zang Y; Cao S; Yang F; Yang Z; Yu W; Lei D; Pan X
Mol Diagn Ther; 2019 Jun; 23(3):407-417. PubMed ID: 30868407
[TBL] [Abstract][Full Text] [Related]
30. Expression of
You MH; Jeon MJ; Kim TY; Kim WB; Shong YK; Kim WG
Endocrinol Metab (Seoul); 2019 Jun; 34(2):203-212. PubMed ID: 31257748
[TBL] [Abstract][Full Text] [Related]
31. Targeting ubiquitin-specific protease 22 suppresses growth and metastasis of anaplastic thyroid carcinoma.
Zhao HD; Tang HL; Liu NN; Zhao YL; Liu QQ; Zhu XS; Jia LT; Gao CF; Yang AG; Li JT
Oncotarget; 2016 May; 7(21):31191-203. PubMed ID: 27145278
[TBL] [Abstract][Full Text] [Related]
32. S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13.
Wang L; Wang X; Liang Y; Diao X; Chen Q
Acta Biochim Pol; 2012; 59(4):593-8. PubMed ID: 23162804
[TBL] [Abstract][Full Text] [Related]
33. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
34. Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer.
Vecchio G; Parascandolo A; Allocca C; Ugolini C; Basolo F; Moracci M; Strazzulli A; Cobucci-Ponzano B; Laukkanen MO; Castellone MD; Tsuchida N
Oncotarget; 2017 Apr; 8(16):27075-27092. PubMed ID: 28404918
[TBL] [Abstract][Full Text] [Related]
35. Targeting TGF-β1 inhibits invasion of anaplastic thyroid carcinoma cell through SMAD2-dependent S100A4-MMP-2/9 signalling.
Zhang K; Liu X; Hao F; Dong A; Chen D
Am J Transl Res; 2016; 8(5):2196-209. PubMed ID: 27347327
[TBL] [Abstract][Full Text] [Related]
36. NGAL controls the metastatic potential of anaplastic thyroid carcinoma cells.
Volpe V; Raia Z; Sanguigno L; Somma D; Mastrovito P; Moscato F; Mellone S; Leonardi A; Pacifico F
J Clin Endocrinol Metab; 2013 Jan; 98(1):228-35. PubMed ID: 23150684
[TBL] [Abstract][Full Text] [Related]
37. MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1.
Zhang W; Ji W; Zhao X
BMC Cancer; 2019 Nov; 19(1):1093. PubMed ID: 31718618
[TBL] [Abstract][Full Text] [Related]
38. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma.
Kim KS; Min JK; Liang ZL; Lee K; Lee JU; Bae KH; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Choi MJ; Jo YS; Kim JM; Shong M
Clin Cancer Res; 2012 Jun; 18(11):3071-8. PubMed ID: 22472175
[TBL] [Abstract][Full Text] [Related]
39. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
40. RNA interference targeting inhibition of S100A4 suppresses cell growth and promotes apoptosis in human laryngeal carcinoma Hep‑2 cells.
Liu J; Fu S; Xu Y; Zheng Z
Mol Med Rep; 2014 Sep; 10(3):1389-94. PubMed ID: 24969174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
